Allspring Global Investments Holdings LLC Increases Stake in Janux Therapeutics, Inc. (NASDAQ:JANX)

Allspring Global Investments Holdings LLC grew its position in shares of Janux Therapeutics, Inc. (NASDAQ:JANX) by 54.0% in the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 9,033 shares of the company’s stock after buying an additional 3,168 shares during the quarter. Allspring Global Investments Holdings LLC’s holdings in Janux Therapeutics were worth $244,000 as of its most recent filing with the SEC.

A number of other large investors also recently bought and sold shares of the company. Russell Investments Group Ltd. raised its position in Janux Therapeutics by 77.7% during the 4th quarter. Russell Investments Group Ltd. now owns 1,011 shares of the company’s stock worth $54,000 after buying an additional 442 shares during the last quarter. Avanza Fonder AB raised its position in Janux Therapeutics by 17.0% during the 1st quarter. Avanza Fonder AB now owns 3,049 shares of the company’s stock worth $86,000 after buying an additional 444 shares during the last quarter. Exchange Traded Concepts LLC raised its position in Janux Therapeutics by 20.4% during the 1st quarter. Exchange Traded Concepts LLC now owns 4,043 shares of the company’s stock worth $109,000 after buying an additional 686 shares during the last quarter. Kennedy Capital Management LLC raised its position in Janux Therapeutics by 7.9% during the 4th quarter. Kennedy Capital Management LLC now owns 12,713 shares of the company’s stock worth $681,000 after buying an additional 928 shares during the last quarter. Finally, MetLife Investment Management LLC grew its stake in shares of Janux Therapeutics by 5.8% during the 4th quarter. MetLife Investment Management LLC now owns 17,298 shares of the company’s stock worth $926,000 after purchasing an additional 949 shares during the period. Hedge funds and other institutional investors own 75.39% of the company’s stock.

Janux Therapeutics Trading Down 1.8%

Shares of NASDAQ JANX opened at $25.15 on Friday. The company’s 50-day moving average price is $24.61 and its 200 day moving average price is $32.40. Janux Therapeutics, Inc. has a 52 week low of $22.48 and a 52 week high of $71.71. The stock has a market cap of $1.49 billion, a price-to-earnings ratio of -18.49 and a beta of 2.86.

Janux Therapeutics (NASDAQ:JANX) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($0.38) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.05. As a group, research analysts expect that Janux Therapeutics, Inc. will post -1.38 earnings per share for the current year.

Analyst Ratings Changes

Separately, Raymond James Financial started coverage on shares of Janux Therapeutics in a report on Friday. They set an “outperform” rating and a $65.00 price objective on the stock. One equities research analyst has rated the stock with a hold rating, nine have issued a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, Janux Therapeutics presently has an average rating of “Buy” and an average target price of $91.89.

Insider Activity

In other news, insider Andrew Hollman Meyer sold 3,334 shares of the company’s stock in a transaction on Monday, April 21st. The stock was sold at an average price of $30.00, for a total value of $100,020.00. Following the sale, the insider directly owned 82,139 shares in the company, valued at $2,464,170. This represents a 3.90% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 8.10% of the stock is owned by corporate insiders.

Janux Therapeutics Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.